BULLETIN: Westar Energy's Sale of Interest in Turkish Power Plant Does Not Affect Rating Nov 04

  • ID: 2041375
  • November 2004
  • Region: Turkey
  • Standard & Poors
1 of 3

NEW YORK (Standard & Poor's) Nov. 18, 2004--Standard & Poor's Ratings Services said today that Westar Energy Inc.'s (BB+/Positive/--) announcement that it has completed the sale of its 9% interest in a natural gas-fired plant located in Turkey to affiliates of Prisma Energy International is supportive of the company's return-to-basics strategy, but has no effect on its rating on Westar. Although financial terms of the transaction were not disclosed, Standard & Poor's does not expect the cash proceeds to Westar to be material. Hence, the sale will not significantly enhance Westar's financial profile. Improved creditworthiness will depend on achieving and sustaining cash flow measures that are solidly investment-grade quality....

Companies mentioned in this report are: Westar Energy Inc.
Action: Bulletin

Standard and Poors RatingsXpress Credit Research provides in-depth coverage of international corporates, financial institutions, insurance companies, utilities, sovereigns and structured finance programs. RatingsXpress Credit Research lets users determine the credit rating of holdings and identify key factors underlying an issuer's creditworthiness, distinguishes the different risk exposures for new and existing deals, and provides an understanding of how their analysts interpret key regulatory, political and environmental events and their economic impact.

Research type: News
This product is a is a brief one-page announcement of no more than 500 words with a quote from the analyst. It is media and investor focused with no accompanying commentary article.

Note: Product cover images may vary from those shown
2 of 3

Westar Energy Inc.

Note: Product cover images may vary from those shown
3 of 3
Note: Product cover images may vary from those shown




Our Clients

  • Fluidigm Corporation
  • Apple, Inc.
  • CEVA Santé Animale
  • Abbott Laboratories Ltd.
  • Merck Group
  • Allergan Inc.
  • Pfizer Inc.